Gary McAuslan is Co-founder and CEO of aCGT Vector, established June 2020, a Cell and Gene Therapy CDMO business, already located and co-locating in cancer hospital centres of excellence in Europe and UK initially, to revolutionalize healthcare provision. A chemistry, manufacturing, and controls expert with over 30 years of pharma expertise bringing ideas from discovery to product approval; Gary McAuslan and co-founder enter the cell therapy sector with a unique set of skills to transform the deployment of transformative and potentially curative precision medicines. Holding a degree in chemistry from The University of Glasgow and an MBA from Trinity College Dublin, McAuslan, co-founder and team bring a credible disruptive offering that will increase patient and clinician access to transformative precision medicines.